ロード中...
Recurrence‐free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate
BACKGROUND: Tigilanol tiglate (TT) is a novel small molecule approved by the European Medicines Agency for intratumoral treatment of mast cell tumors (MCTs) in dogs. In a randomized controlled clinical efficacy and safety study in the United States, 85 of 116 dogs that received a single TT injection...
保存先:
| 出版年: | J Vet Intern Med |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7848364/ https://ncbi.nlm.nih.gov/pubmed/33350511 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jvim.16018 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|